CARB-X funds VenatoRx to support development of new class of oral antibiotics to treat multi-drug-resistant gonorrhoea

This article was originally published here

Health officials have identified MDR gonorrhea, a sexually transmitted bacteria, as an urgent global public health threat, exacerbated by limited diagnostics and treatment options. Each year, according to

The post CARB-X funds VenatoRx to support development of new class of oral antibiotics to treat multi-drug-resistant gonorrhoea appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply